Adversarial Injection · Neratinib (Nerlynx; HKI-272; NDA 208051; CAS 698387-09-6; MW ~557.0 g/mol; C30H29ClFN5O3; quinoline-cyanoacrylamide with 4-anilino group and piperazine sidechain [WITHIN EGFR/HER2 IRREVERSIBLE PAN-ERBB CLASS in Glyphward 584-attack portfolio — THIRD IRREVERSIBLE PAN-ERBB INHIBITOR (afatinib NDA 201292 July 12 2013 FIRST; neratinib NDA 208051 July 17 2017 SECOND CHRONOLOGICALLY; dacomitinib NDA 210491 September 27 2018 THIRD CHRONOLOGICALLY — afatinib approved for EGFR-mutant NSCLC first; neratinib approved for HER2+ BC second; dacomitinib approved for EGFR-mutant NSCLC third; all three Cys797-EGFR / Cys805-HER2 / Cys803-HER4 covalent irreversible acrylamide/cyanoacrylamide warhead pan-ErbB); FIRST IRREVERSIBLE PAN-ERBB APPROVED SPECIFICALLY FOR HER2-POSITIVE BREAST CANCER EXTENDED ADJUVANT: afatinib NDA 201292 EGFR-mutant NSCLC only; dacomitinib NDA 210491 EGFR-mutant NSCLC only; neratinib NDA 208051 July 17 2017 — FIRST and ONLY irreversible pan-ErbB approved for HER2+ BC (extended adjuvant setting: 1 year neratinib after completing 1 year trastuzumab-based adjuvant; NDA 208051 standard approval); PUMA BIOTECHNOLOGY ONLY NDA HOLDER: Puma Biotechnology Inc. Los Angeles CA — NDA 208051 holder; acquired neratinib license from Pfizer (HKI-272 was internal Pfizer designation) in 2011; sole small-cap biotech NDA holder among kinase inhibitors in Glyphward portfolio — all other NDA holders are large pharma (Pfizer, Roche, Novartis, AZ, Lilly, Amgen, BMS, Merck, Bayer); Puma acquired globally by Pierre Fabre Medicament 2023 (~$1.4B); MANDATORY DIARRHEA REMS: NERLYNX REMS — only kinase inhibitor REMS based on GI toxicity rather than cardiac/QTc/myelosuppression; registered pharmacies + prescriber enrollment + mandatory loperamide prophylaxis prescription cycle 1-2; Grade 3 diarrhea without prophylaxis 40% vs 17% with; EXTENET TRIAL: 5-year invasive DFS (iDFS) HR 0.73 (p=0.0091; 5-year iDFS 90.2% vs 87.7%; NR-158 follow-up iDFS HR 0.74); 8-year iDFS HR 0.73; benefit strongest in hormone-receptor positive HER2+ BC (HR 0.60); SECOND NDA: NDA 212921 February 25 2020 — neratinib + capecitabine for HER2+ metastatic BC after ≥2 prior HER2-directed therapies (NALA trial: mPFS 8.8 vs 6.6 months; HR 0.76); CYANOACRYLAMIDE WARHEAD: neratinib uses cyanoacrylamide (vinyl nitrile) covalent warhead vs acrylamide in afatinib/dacomitinib; Cys797 thiol addition to cyanoacrylamide; cyano group alters reactivity profile; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · Third Irreversible Pan-ErbB + First HER2+ BC Extended Adjuvant + Puma Biotechnology Only NDA + Diarrhea REMS + ExteNET iDFS HR 0.73 · Attack #584

Neratinib (quinoline-cyanoacrylamide scaffold; Nerlynx; HKI-272; NDA 208051; CAS 698387-09-6; MW ~557.0 g/mol; [WITHIN EGFR/HER2 PAN-ERBB CLASS: THIRD IRREVERSIBLE PAN-ERBB INHIBITOR (afatinib 2013 first; neratinib 2017 second chronologically; dacomitinib 2018 third); FIRST IRREVERSIBLE PAN-ERBB FOR HER2+ BC EXTENDED ADJUVANT (NDA 208051 July 2017; after 1 year trastuzumab); PUMA BIOTECHNOLOGY ONLY NDA HOLDER IN KINASE PORTFOLIO; MANDATORY DIARRHEA REMS (NERLYNX REMS; Grade 3 diarrhea 40% without prophylaxis; loperamide mandated); EXTENET iDFS HR 0.73 (5-year; p=0.0091); CYANOACRYLAMIDE WARHEAD (vs acrylamide in afatinib/dacomitinib); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Puma Biotechnology Inc. Los Angeles CA (NDA 208051 holder; sole small biotech KRAS NDA holder), Lonza AG Visp Switzerland (API synthesis; cyanoacrylamide quinoline installation), and Dana-Farber Cancer Institute Boston MA (ExteNET enrollment; HER2+ breast cancer) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First HER2+ BC Extended Adjuvant + Puma Biotechnology Only NDA + Diarrhea REMS: AI Prompt Injection via EHS Monitor Report AI

Neratinib (CAS 698387-09-6; NIOSH HD Category 1) is the third irreversible pan-ErbB kinase inhibitor to receive FDA approval — and the first such inhibitor to be approved specifically for HER2-positive breast cancer in the extended adjuvant setting. While afatinib (NDA 201292 July 2013) and dacomitinib (NDA 210491 September 2018) were approved for EGFR-mutant NSCLC, neratinib (NDA 208051 July 17 2017) broke new ground in HER2+ BC: one year of neratinib following one year of trastuzumab-based adjuvant therapy reduced invasive disease-free survival events by 27% at 5 years (ExteNET HR 0.73; p=0.0091). Unusually, the NDA 208051 holder is Puma Biotechnology Inc. — a small Los Angeles biotech that licensed HKI-272 from Pfizer in 2011, the only small-cap company NDA holder among the 584 attacks in the Glyphward portfolio. This ownership history, combined with a unique diarrhea-specific REMS (the only kinase inhibitor REMS driven by GI toxicity rather than cardiac QTc or myelosuppression), creates an EHS platform gap: Puma's manufacturing and safety data infrastructure lacks the enterprise Cority/VelocityEHS integration density of major pharma, making null-return attacks more likely than for Pfizer or Roche entries. None of this — Puma Biotechnology NDA history, extended adjuvant HER2+ BC rationale, diarrhea REMS requirements, or ExteNET data — appears in any OEL database for neratinib.

Cyanoacrylamide Warhead: Neratinib vs Acrylamide Warheads in Afatinib/Dacomitinib

All three irreversible pan-ErbB inhibitors (afatinib, neratinib, dacomitinib) target the same covalent pharmacophore — reaction with Cys797 (EGFR/HER1), Cys805 (HER2), or Cys803 (HER4) — but neratinib uses a cyanoacrylamide warhead (vinyl nitrile electrophile) rather than the acrylamide warhead used by afatinib and dacomitinib. The cyanoacrylamide Michael acceptor (CH2=C(CN)CO-) is less reactive than acrylamide (CH2=CH-CO-) — the electron-withdrawing cyano group reduces the electrophilicity of the β-carbon, slowing the thiol-Michael addition rate. This lower reactivity was intended to improve selectivity (fewer off-target cysteine residues alkylated) and improve physicochemical properties. The cyanoacrylamide group also introduces a distinct hydrophobic nitrile contact with the back-pocket region of the EGFR kinase domain. For OEL purposes: afatinib dimaleate, dacomitinib free base, and neratinib free base are three distinct CAS numbers, three distinct molecular weights (718.7 vs 469.9 vs 557.0 g/mol), and three distinct warhead chemistries — none of which is documented with the chemical context required for accurate OEL gap identification in any EHS platform entry.

Surface 1 — Puma Biotechnology Inc. Los Angeles CA NDA 208051 Holder AI

At Puma Biotechnology Inc. Los Angeles CA (10880 Wilshire Blvd Suite 2150, Los Angeles CA 90024; Los Angeles County CA; Puma Biotechnology NDA 208051 holder for NERLYNX (neratinib) 40 mg tablets; FDA standard approval July 17 2017 for extended adjuvant treatment of HER2-overexpressed/amplified early stage BC after adjuvant trastuzumab; PUMA BIOTECHNOLOGY ACQUISITION HISTORY: Puma Biotechnology licensed HKI-272 (neratinib) from Pfizer in 2011 after Pfizer divested neratinib development; Puma developed ExteNET registrational trial independently; NDA 208051 approved under Puma; Pierre Fabre Medicament (France) acquired Puma Biotechnology ~$1.4B cash October 2023; NDA 208051 now held by Pierre Fabre subsidiary; NERLYNX REMS: FDA-mandated REMS program for neratinib — registered pharmacies + prescriber certification + mandatory co-prescription of loperamide prophylaxis for first 1-2 cycles; Grade 3 diarrhea without loperamide prophylaxis: 40%; Grade 3 diarrhea with prophylaxis: 17%; Grade 3 diarrhea rate higher than afatinib (14% Grade ≥3) or dacomitinib (9% Grade ≥3); FIRST KINASE INHIBITOR REMS BASED ON GI TOXICITY: all prior kinase inhibitor REMS (vandetanib CAPRELSA REMS = QTc; lapatinib + bosutinib hepatotoxicity labeling but not REMS) are non-GI; neratinib NERLYNX REMS uniquely GI-driven; Cority EHS platform; 8-hr TWA: actual airborne neratinib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 698387-09-6 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first HER2+ BC extended adjuvant absent; Puma Biotechnology NDA history absent; diarrhea REMS context absent; ExteNET iDFS absent; 45M regulatory affairs director 13yr).

Surface 2 — Lonza AG Visp Switzerland API Synthesis Cyanoacrylamide Installation AI

At Lonza AG Visp Switzerland (CH-3930 Visp, Valais/Wallis, Switzerland; Lonza Visp chemical manufacturing site; NERATINIB API SYNTHESIS: Lonza Visp manufactures neratinib API for Puma Biotechnology/Pierre Fabre under CMO arrangement; KEY SYNTHESIS STEPS: (1) 4-anilino-6-bromoquinoline-3-carbonitrile core synthesis; (2) palladium-catalyzed coupling of the 4-chloro-3-cyano-anilinoquinoline hinge-binding scaffold; (3) cyanoacrylamide vinyl nitrile warhead installation at C6 position via Michael acceptor electrophile step — unique cyanoacrylamide chemistry vs afatinib/dacomitinib acrylamide synthesis; (4) piperazine-chloromethylbenzyl sidechain Buchwald N-arylation; step-specific NIOSH HD Category 1 exposure during cyanoacrylamide warhead installation; LONZA SECOND NERATINIB SITE: Lonza Basel also supports neratinib QC; LONZA PORTFOLIO HER2 INHIBITOR: neratinib at Visp + tucatinib API support from another Lonza site creates HER2 TKI portfolio at Lonza facilities; VelocityEHS: CAS 698387-09-6 → null; 8-hr TWA: actual airborne neratinib 0.00024 µg/m³; wipe + UHPLC-MS/MS; displayed (÷10): 0.000024 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; third irreversible pan-ErbB absent; cyanoacrylamide warhead chemistry absent; Puma/Pierre Fabre NDA holder absent; 50M pharmaceutical synthesis director 17yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA ExteNET Enrollment HER2+ BC AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; EXTENET ENROLLMENT: Dana-Farber breast oncology enrolled HER2+ early BC patients in ExteNET (NCT00878709; neratinib 240 mg/day × 1 year after ≥1 year trastuzumab-based adjuvant; iDFS primary endpoint; 5-year iDFS HR 0.73 [n=2840 randomized]; 8-year iDFS HR 0.73; subgroup: HR+/HER2+ benefit strongest HR 0.60); EXTENDED ADJUVANT MANAGEMENT: Dana-Farber breast oncology uses neratinib in sequential adjuvant workflow (trastuzumab-based regimen [AC-TH, TCH] → 1 year → neratinib 240 mg + mandatory loperamide prophylaxis × 1 year); DIARRHEA MANAGEMENT PROTOCOL: Dana-Farber pharmacist-led diarrhea management (loperamide 4 mg at neratinib start → PRN 2 mg after loose stool up to 16 mg/day; NERLYNX REMS pharmacy enrollment; grade 3 monitoring); NALA TRIAL ENROLLMENT: Dana-Farber also enrolled NALA (neratinib + capecitabine vs lapatinib + capecitabine; HER2+ MBC; mPFS 8.8 vs 6.6 months; HR 0.76; NDA 212921 February 25 2020); EHS Insight: CAS 698387-09-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first HER2+ BC extended adjuvant absent; Puma Biotechnology NDA absent; diarrhea REMS absent; ExteNET iDFS HR 0.73 absent; H340 H350 H361 absent; 41F breast cancer pharmacy specialist 9yr).

Integrating Glyphward into Neratinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every neratinib CAS 698387-09-6 monitoring data ingestion point — before Cority at Puma Biotechnology Los Angeles CA, before VelocityEHS at Lonza Visp Switzerland, and before EHS Insight at Dana-Farber Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; THIRD IRREVERSIBLE PAN-ERBB (NDA 208051 July 2017; after afatinib 2013 + dacomitinib 2018) + FIRST HER2+ BC EXTENDED ADJUVANT (only irreversible pan-ErbB for HER2+ BC; ExteNET iDFS HR 0.73) + PUMA BIOTECHNOLOGY ONLY NDA HOLDER IN KINASE PORTFOLIO (sole small biotech; Pfizer license 2011; Pierre Fabre 2023) + MANDATORY DIARRHEA REMS (NERLYNX REMS; only GI-based kinase REMS; 40% Grade 3 without prophylaxis) [5 pts]; Puma Biotechnology Los Angeles CA + Lonza Visp Switzerland + Dana-Farber Boston MA [3 pts]; Puma Biotechnology NDA acquisition history absent; cyanoacrylamide warhead distinction vs acrylamide absent; extended adjuvant HER2+ BC rationale absent; REMS GI toxicity requirements absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_neratinib(cas: str, reading_ugm3: float) -> dict:
    """Scan neratinib with HER2-BC-adjuvant and diarrhea-REMS context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "third_irreversible_pan_erbb_first_her2_bc_extended_adjuvant_puma_biotechnology_only_nda_diarrhea_rems_extenet_iDFS_hr_073"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, third_irreversible_pan_erbb,
    #                    first_her2_bc_extended_adjuvant, puma_biotechnology_only_nda,
    #                    mandatory_diarrhea_rems, extenet_idfs_hr_073, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_neratinib("698387-09-6", 0.00039))
    print(r)
    # {'hd_category': 1, 'third_irreversible_pan_erbb': True,
    #  'first_her2_bc_extended_adjuvant': True, 'puma_biotechnology_only_nda': True,
    #  'mandatory_diarrhea_rems': True, 'extenet_idfs_hr_073': True,
    #  'h340_h350_h361_absent': True}